- Home
- ABEO
as 04-01-2025 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 237.4M | IPO Year: | 1980 |
| Target Price: | $17.00 | AVG Volume (30 days): | 493.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.05 - $8.45 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 561.86% |
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | ABEO | Chief Executive Officer | Mar 31 '25 | Sell | $4.78 | 25,000 | $119,500.00 | 1,355,322 | |
| Alvino Mark | ABEO | Director | Jan 29 '25 | Sell | $5.38 | 4,000 | $21,520.00 | 64,334 | |
| Alvino Mark | ABEO | Director | Jan 21 '25 | Sell | $5.10 | 4,000 | $20,400.00 | 64,334 |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks Small Cap Research
9 days ago
ABEO: Countdown to PDUFA Date of April 29, 2025…
GuruFocus.com
12 days ago
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
Thomson Reuters StreetEvents
12 days ago
Q4 2024 Abeona Therapeutics Inc Earnings Call
GlobeNewswire
13 days ago
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
GlobeNewswire
a month ago
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
TipRanks
a month ago
Abeona Therapeutics announces new employee inducement grants
GlobeNewswire
a month ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.